Herantis Pharma publishes newsletter for March-April

Herantis Pharma publishes newsletter for March-April

Herantis Pharma Plc
Press release 6 May 2019 at 9:00 am

Herantis Pharma plc (“Herantis”) has published its newsletter for March-April. The newsletter is also attached to this press release.

Herantis’ newsletter is published every other month on the company’s web site. It is also available by email subscription.

Further information:

Herantis Pharma plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson’s disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.

Distribution:

Main media
www.herantis.com